Sofosbuvir-velpatasvir-voxilaprevir provides salvage therapy for NS5A failures
Mark Fuerst
Advertisement
Articles by Mark Fuerst
Despite the availability of new, highly successful direct-acting antiviral (DAA) regimens, more than one third of chronic hepatitis C (HCV) patients are denied access to treatment by their insurance provider, according to a new study.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
Inside CMS's push to rebalance Medicare payments toward primary care
2
Latest on the cyclospora outbreak; first oral PCSK9 inhibitor approved; AHA update: how much coffee is heart-safe? — Morning Medical Update
3
Why ChatGPT favors hospitals over independent practices
4
CMS expands health care fraud-fighting efforts as it withholds $1B in Medicaid funds
5